| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to new imidazolone derivatives used as drugs being kinase inhibitors, described by formula(I), wherein; Rrepresents a C1-C3 alkyl radical or a hydrogen atom, and/or an aryl radical, Aris specified inor, R represents the group R-S-, Ris thereby specified in the radicals like T-(CH), wherein n=0, 1, 2 or 3, and Trepresents a metal, vinyl, alkyl, alkynyl, nitrile, C3- or C4-cycloalkyl radical, hal, Z-O, Z-CO, wherein Z represents C1-C3 alkyl or hal, hal represents F, Cl, Br or I, or the group CCl, or the group R-NH-, Ris thereby specified in the radicals like T-(CH), wherein n=0, 1 or 2, and Trepresents a metal, vinyl radical, Z-O, Z-CONH-, -CH-(OZ), ZCO, wherein Z represents H or C1-C4 linear or branched alkyl, NH, C3-cycloalkyl, aryl, substituted aryl, or Rrepresents H, or the group R-CONH-, Ris thereby specified in C3-C5 branched alkyl, or Ar?or Ar-3-, Aris specified in a phenyl radical, substituted phenyl or benzodioxolyl; and have ICless than 5 mcM.EFFECT: invention also refers to pharmaceutical compositions based on the compounds of formula I for treating neurodegenerative disorders and to using these compounds as DYRKIA inhibitors.11 cl, 2 tbl, 8 ex |
